Ensign Peak Advisors
KRTX

Ensign Peak Advisors’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Ensign Peak Advisors’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-146,467
Closed -$46.4M – 1770
2023
Q4 		$46.4M Buy
146,467
+5,129
+4% +$997K 0.09% 196
2023
Q3 		$23.9M Sell
141,338
-35,726
-20% -$6.72M 0.05% 254
2023
Q2 		$38.4M Buy
177,064
+35,749
+25% +$7.66M 0.08% 203
2023
Q1 		$25.7M Hold
141,315
– – 0.06% 254
2022
Q4 		$27.8M Sell
141,315
-34,498
-20% -$7.4M 0.06% 247
2022
Q3 		$39.5M Sell
175,813
-40,144
-19% -$8.13M 0.1% 184
2022
Q2 		$27.3M Sell
215,957
-43,004
-17% -$4.94M 0.06% 230
2022
Q1 		$32.8M Buy
258,961
+2,850
+1% +$321K 0.07% 220
2021
Q4 		$33.5M Sell
256,111
-13,408
-5% -$1.73M 0.06% 241
2021
Q3 		$33M Sell
269,519
-16,787
-6% -$1.94M 0.07% 229
2021
Q2 		$32.6M Buy
286,306
+3,313
+1% +$387K 0.07% 241
2021
Q1 		$34M Buy
282,993
+84,105
+42% +$9.53M 0.07% 226
2020
Q4 		$20.2M Buy
198,888
+26,996
+16% +$2.5M 0.05% 312
2020
Q3 		$13.3M Buy
171,892
+79,752
+87% +$6.8M 0.03% 385
2020
Q2 		$10.3M Buy
92,140
+2,947
+3% +$256K 0.03% 421
2020
Q1 		$6.42M Sell
89,193
-14,273
-14% -$1.22M 0.02% 451
2019
Q4 		$7.79M Buy
+103,466
New +$4.53M 0.02% 516

Other funds holding KRTX

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

Ensign Peak Advisors's KRTX Position: Q1 2024 in Review

Ensign Peak Advisors sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 146,467 shares — an estimated $46.4M sold.

Ensign Peak Advisors first reported a position in KRTX in Q4 2019 and held it in 17 quarters. The position peaked at $46.4M in Q4 2023. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

  • Ensign Peak Advisors reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Ensign Peak Advisors sold 146,467 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $46.4M.
  • Ensign Peak Advisors first reported a position in Karuna Therapeutics, Inc. Common Stock in Q4 2019 and held it in 17 quarters.
  • Ensign Peak Advisors's Karuna Therapeutics, Inc. Common Stock position peaked at $46.4M in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Ensign Peak Advisors's 13F filing for Q1 2024, filed 14 May 2024.